Edition:
United Kingdom

BioLife Solutions Inc (BLFS.OQ)

BLFS.OQ on NASDAQ Stock Exchange Capital Market

5.79USD
15 Dec 2017
Change (% chg)

$-0.06 (-1.03%)
Prev Close
$5.85
Open
$5.88
Day's High
$5.89
Day's Low
$5.77
Volume
11,796
Avg. Vol
38,053
52-wk High
$7.53
52-wk Low
$1.52

Chart for

About

BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management... (more)

Overall

Beta: 0.27
Market Cap(Mil.): $76.06
Shares Outstanding(Mil.): 13.23
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Biolife Solutions Executes Supply Agreement With Iovance Biotherapeutics

* BIOLIFE SOLUTIONS EXECUTES SUPPLY AGREEMENT WITH IOVANCE BIOTHERAPEUTICS

13 Dec 2017

BRIEF-Biolife Solutions Executes Additional Long-Term Supply Agreement With Leading T Cell Therapy Customer

* BIOLIFE SOLUTIONS EXECUTES ADDITIONAL LONG-TERM SUPPLY AGREEMENT WITH LEADING T CELL THERAPY CUSTOMER Source text for Eikon: Further company coverage:

29 Nov 2017

BRIEF-BioLife Solutions posts Q3 loss per share $0.03

* Biolife Solutions announces third quarter 2017 financial results

09 Nov 2017

BRIEF-Biolife Solutions to report Q3 results and provide business update on Nov 9

* Biolife Solutions to report third quarter 2017 financial results and provide business update on November 9, 2017 Source text for Eikon: Further company coverage:

02 Nov 2017

BRIEF-BioLife Solutions CryoStor cell freeze media embedded in Cellular Biomedicine Group clinical trial of AlloJoin

* BioLife Solutions CryoStor cell freeze media embedded in Cellular Biomedicine Group clinical trial of AlloJoin Source text for Eikon: Further company coverage:

19 Sep 2017

BRIEF-BioLife Solutions executes supply agreement with Celyad for CryoStor

* Biolife Solutions executes supply agreement with Celyad for CryoStor use in natural killer receptor based t-cell (nkr-t) platform targeting solid tumors and blood cancers

31 Jul 2017

BRIEF-Biolife Solutions modifies existing credit facility

* Biolife Solutions Inc - has reached an agreement with wavi holding to modify its existing credit facility effective June 30, 2017

05 Jul 2017

Competitors

Earnings vs. Estimates